Should AbbVie (ABBV) Stock Get More Attention After Its Latest Pipeline Progress?

Simply Wall St.11-10

AbbVie (NYSE: ABBV) reports positive Phase 3 data for QULIPTA in migraine prevention, adding fresh late stage evidence for the drug. The company submits a Biologics License Application to the FDA for ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2682361036?lang=en_US&edition=fundamental","thumbnail":"https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=240/https://images.simplywall.st/asset/company-cover/141885706-card/1789002767761","is_english":true,"pubTime":"2026-11-10 15:15","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2682361036","market":"us","top_or_hot":-1,"title":"Should AbbVie (ABBV) Stock Get More Attention After Its Latest Pipeline Progress?","media":"Simply Wall St.","content":"<div>\n<p>AbbVie (NYSE: ABBV) reports positive Phase 3 data for QULIPTA in migraine prevention, adding fresh late stage evidence for the drug. The company submits a Biologics License Application to the FDA for ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-abbv/abbvie/news/should-abbvie-abbv-stock-get-more-attention-after-its-latest\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Should AbbVie (ABBV) Stock Get More Attention After Its Latest Pipeline Progress?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nShould AbbVie (ABBV) Stock Get More Attention After Its Latest Pipeline Progress?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-11-10 15:15 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-abbv/abbvie/news/should-abbvie-abbv-stock-get-more-attention-after-its-latest><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>AbbVie (NYSE: ABBV) reports positive Phase 3 data for QULIPTA in migraine prevention, adding fresh late stage evidence for the drug. The company submits a Biologics License Application to the FDA for ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-abbv/abbvie/news/should-abbvie-abbv-stock-get-more-attention-after-its-latest\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1551013342.USD","symbol_name":"Allianz Income and Growth Cl AMg2 DIS USD","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-abbv/abbvie/news/should-abbvie-abbv-stock-get-more-attention-after-its-latest","article_id":"2682361036","we_media_id":null,"thumbnails":["https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=240/https://images.simplywall.st/asset/company-cover/141885706-card/1789002767761"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-abbv/abbvie/news/should-abbvie-abbv-stock-get-more-attention-after-its-latest","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2682361036","pubTimestamp":1794294944,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"SSasha JovanovicNovember 10, 2026","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU1551013342.USD":"Allianz Income and Growth Cl AMg2 DIS USD","XLV":"健康照护类股ETF-SPDR","IE000BZT7R73.USD":"RQI GLOBAL \"I\" (USD) ACC","IYH":"iShares U.S. Healthcare ETF","LU1267930490.SGD":"TEMPLETON GLOBAL EQUITY INCOME \"AS\" (SGD) INC A","LU0211328371.USD":"TEMPLETON GLOBAL EQUITY INCOME \"A\" (MDIS) (USD)   INC","LU0320765646.SGD":"FTIF - Franklin Income A MDIS SGD-H1","TRUH":"VanEck Healthcare TruSector ETF","MEDX":"HORIZON KINETICS MEDICAL ETF","LU0395794307.EUR":"JPM GLOBAL INCOME (DIV) \"A\" (EUR) INC","LU0868494708.USD":"UBS (LUX) EQUITY SICAV - US TOTAL YIELD SUSTAINABLE \"P\" (USD) INC","JDOC":"JPMORGAN HEALTHCARE LEADERS ETF","IE0002270589.USD":"LEGG MASON CLEARBRIDGE VALUE \"A\" (USD) INC","LU0234572021.USD":"高盛美国核心股票组合Acc","FTXH":"First Trust Nasdaq Pharmaceuticals ETF","RXL":"ProShares Ultra Health Care","SG9999015945.SGD":"LionGlobal Disruptive Innovation Fund A SGD","ABBV":"艾伯维公司","AGNG":"Global X Aging Population ETF","PJP":"INVESCO PHARMACEUTICALS ETF","LU1670628061.USD":"M&G (LUX) NORTH AMERICAN DIVIDEND \"A\" (USD) INC","SG9999001440.SGD":"United Global Dividend Equity Fund A SGD Dist","LU1989772840.SGD":"CPR Invest - Climate Action A2 Acc SGD-H","LU0124676726.USD":"AB SICAV I - SUSTAINABLE US THEMATIC PORTFOLIO \"A\" (USD) ACC","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","IE0004445239.USD":"JANUS HENDERSON US FORTY \"A2\" (USD) ACC","LU0310800379.SGD":"FTIF - Templeton Global A Acc SGD","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","GLAM":"Corgi Beauty, Skincare & Aesthetics ETF","LU0949170772.SGD":"Blackrock Global Equity Income A6 SGD-H","IXJ":"全球医疗业ETF-iShares","VHT":"Vanguard Health Care ETF","LU2129689431.USD":"FRANKLIN GLOBAL INCOME \"A\" (USD) ACC","FHLC":"Fidelity MSCI Health Care Index","LU0203347892.USD":"SCHRODER ISF QEP GLOBAL ACTIVE VALLUE \"A\" (USD)  INC AV","LU2237443978.SGD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A Acc SGD-H","LU0820561909.HKD":"ALLIANZ INCOME AND GROWTH \"AM\" (HKD) INC","LU1003077747.HKD":"BGF GLOBAL EQUITY INCOME \"A6\" (HKDHDG) INC","PPH":"VanEck Pharmaceutical ETF","LU0234570918.USD":"高盛全球核心股票组合Acc Close","LU2357305700.SGD":"Allianz Global Artificial Intelligence ET H2-SGD","LU0310799852.SGD":"FTIF - Templeton Global Equity Income A MDIS SGD","LU0289961442.SGD":"SUSTAINABLE GLOBAL THEMATIC PORTFOLIO \"AX\" (SGD) ACC","LU1670627923.USD":"M&G (LUX) NORTH AMERICAN DIVIDEND \"A\" (USD) ACC","IE000SO60NU8.SGD":"RQI GLOBAL \"I\" (SGDHDG) ACC A","LU0661504455.SGD":"Blackrock Global Equity Income A5 SGD-H","IE00B19Z3581.USD":"Legg Mason ClearBridge - Value A Acc USD","LU0942090050.USD":"UBS (LUX) EQUITY SICAV - US TOTAL YIELD SUSTAINABLE \"P\" (USD)  INC","LU0256863902.USD":"ALLIANZ US EQUITY \"AT\" (USD) ACC","PRGS":"Progress Software Corporation"},"translate_title":"艾伯维 (ABBV) 股票在最新管道进展后是否应该受到更多关注？","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"FTXH":0.6,"AGNG":0.6,"RXL":0.6,"TRUH":0.6,"PPH":0.6,"IXJ":0.6,"MEDX":0.6,"PJP":0.6,"XLV":0.6,"FHLC":0.6,"JDOC":0.6,"PRGS":1.5,"IYH":0.6,"VHT":0.6,"GLAM":0.6,"ABBV":1.5},"content_text":"AbbVie (NYSE: ABBV) reports positive Phase 3 data for QULIPTA in migraine prevention, adding fresh late stage evidence for the drug. The company submits a Biologics License Application to the FDA for etentamig in multiple myeloma, seeking approval as a new oncology therapy. Both updates expand AbbVie’s late stage pipeline in migraine and blood cancer, two large and highly competitive treatment areas. QULIPTA’s Phase 3 success and the etentamig filing are only part of the broader AbbVie story investors should weigh carefully. Our analysis turns up 4 warning signs for AbbVie as well.  This focus on migraine and oncology is shared by a wider group of healthcare players that also push hard into AI supported drug development, and those peers are worth a closer look through 36 healthcare AI stocks. NYSE:ABBV Earnings & Revenue Growth as at Nov 2026 AbbVie is a research driven biopharmaceutical group that develops, manufactures, and sells medicines across multiple disease areas, so progress in migraine and multiple myeloma fits into a broad portfolio rather than a single product bet. With a market value of about $514.9b, the business already sits among the largest biotechs globally, which shapes how investors may think about the impact of any one late stage program. 3 things going right for AbbVie that this headline doesn't cover. AdvertisementQULIPTA and etentamig push AbbVie’s diversification story further, not in a new direction For investors following AbbVie, this migraine and multiple myeloma update mostly reinforces the existing Narrative rather than rewriting it. Positive late stage data for QULIPTA and the etentamig filing align with the idea that new neuroscience and oncology drugs need to replace revenue from older blockbusters such as Humira and Imbruvica. The news supports the catalyst that analysts already highlight, which is execution on a broad late stage pipeline spread across immunology, neuroscience and cancer, rather than dependence on a single product. See how these catalysts shape AbbVie's path to a $306 fair value. The real proof point now is how regulators respond to etentamig and how QULIPTA usage trends evolve through 2027. Investors can watch for an FDA decision on etentamig and subsequent launch metrics, along with reported prescription and revenue contributions from QULIPTA in upcoming quarterly results, to see whether these assets genuinely carry more of AbbVie’s post Humira earnings mix. The AbbVie question headlines skip, but your portfolio cannot Big earnings stories often hinge on a single figure, yet smaller details in AbbVie’s reported results can change how reliable that headline really is. See what our checks flag about the quality of AbbVie's earnings. This article is general in nature and was produced with the assistance of AI automation,\n        based on data and analysis from Simply Wall St. We provide commentary based on historical data\n        and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n        financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n        Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n        Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.53.0","shortVersion":"4.53.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2682361036","isCrawlerRequest":true}